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ABSTRACT 22 
Among non-coding RNAs, microRNAs (miRNAs) have been most extensively studied and their biology has repeatedly been 23 
proven critical for central nervous system pathological conditions. The diagnostic value of several miRNAs was appraised in 24 
pediatric dysembryoplastic neuroepithelial tumors (DNETS) using miRNA microarrays and receiving operating characteristic 25 
curves analyses. Overall, 5 pediatric DNETs were studied. As controls, 17 samples were used; The First-Choice Human Brain 26 
Reference RNA and 16 samples from deceased children who underwent autopsy and were not present with any brain 27 
malignancy. The miRNA extraction was carried out using the mirVANA miRNA isolation kit, while the experimental 28 
approach included miRNA microarrays covering 1211 miRNAs. Quantitative Real-Time Polymerase Chain Reaction was 29 
performed to validate the expression profiles of miR-1909* and miR-3138 in all samples initially screened with miRNA 30 
microarrays. Our findings indicated that miR-3138 might act as a tumor suppressor gene when down-regulated and miR-31 
1909* as a putative oncogenic molecule when up-regulated in pediatric DNETs compared to the control cohort. Subsequently, 32 
both miRNA signatures might serve as putative diagnostic biomarkers for pediatric DNETs.  33 
 34 
 35 
 36 
 37 
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INTRODUCTION 41 
Dysembryoplastic neuroepthelial tumors (DNETs) are rare, benign glioneuronal tumors, which become manifest during 42 
childhood, and are most commonly located in the temporal lobe [1, 2]. According to the World Health Organization 43 
classification system, DNETs have been classified as grade I and they have been included as mixed neuroglial tumors [3]. 44 
Malignant transformation of DNETS has been rarely described [4], while previous reports also suggested infrequent 45 
aggressive and recurrent behavior [5]. As slow-growing tumors though, they have been increasingly documented as a cause 46 
of epilepsy in young children [4]. As stated by Qaddoumi et al. (2010), clinically, DNETs present as seizures before the age 47 
of 20 years in patients with normal intelligence quotient [6]. Seizures add a significant burden, since their presence affords an 48 
important risk factor for long-term disability [7]. Moreover, seizures can be at times, life-threatening themselves with 49 
increasing pediatric brain malignancy survivor’s risk of suicide into adulthood [8, 2]. 50 
 51 
MicroRNAs (miRNAs) are small non-coding RNAs, which regulate gene expression and silence a wide range of target genes 52 
[9]. MicroRNAs impact vital cellular and physiological processes, while their aberrant expression has been linked to a plethora 53 
of serious diseases, including cancer [10]. Notably, several previous reports suggested that miRNAs are essential regulators 54 
of many of the key pathways implicated in the pathogenesis and progression of pediatric central nervous system (CNS) 55 
malignancies [11-13]. Recent evidence also indicated that miRNAs can be used to detain changes in neurons, which makes 56 
them ideal putative biomarkers for central nervous system pathology [10]. Previous reports have demonstrated their use as 57 
potential diagnostic and prognostic biomarkers as well as therapy related targets of pediatric CNS neoplasms [11, 14, 15].  58 
 59 
Based on these sightings, the current study was undertaken to ascertain putative miRNA signatures in pediatric DNETs to 60 
provide additional evidence regarding the early and reliable diagnosis of the disease. To our knowledge, the present report is 61 
the first to identify miRNA signatures in DNETs. Our findings seemed to provide novel insights into the potential diagnostic 62 
properties of certain miRNAs in pediatric DNETs.  63 
 64 
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MATERIALS AND METHODS 66 
Patients and Tumor samples 67 
Overall, resected brain tumors were studied from children diagnosed with dysembryoplastic neuroepithelial tumors (DNETs) 68 
(n=5) diagnosed according to the 2007 WHO criteria [16]. As controls, 17 samples were used; The First-Choice Human Brain 69 
Reference RNA was used (Ambion, Austin, TX, USA) and 16 samples were obtained from deceased children who underwent 70 
autopsy and were not present with any brain distortion, including the following anatomic locations: cerebellum (n=4), medulla 71 
oblongata (n=4), parietal lobe (n=4) and temporal lobe (n=4). The patient cohort included 2 males and 3 females, aged from 72 
4.02 to 12.05 years. The median age of DNET patients was 7.07 years, whilst the median age of the non-malignant cohort was 73 
9 years. The patients’ clinicopathologic characteristics are presented in Table 1. All samples were snap-frozen during resection 74 
and stored at -80oC until use. The present study was conducted with the approval of “Aghia Sophia” Children’s Hospital Ethics 75 
Committee (Protocol No. 11685/11-8-2004). Informed consent was obtained from the parents of all chlidren included in the 76 
study.” 77 
 78 
MicroRNA Profiling  79 
The miRNA profiling was performed as previously described by Braoudaki et al., 2014. Total RNA and miRNAs were 80 
extracted using the Trizol standard protocol (Invitrogen, Carlsbad, CA) and the mirVANA miRNA isolation kit (Ambion, 81 
Austin, TX) [11]. Labelling and hybridization were carried out using the LabelIT miRNA labelling kit (Mirus Bio LLC, USA) 82 
following manufacturer’s instructions. Samples were hybridized to Applied MicroArrays (miRlink Bioarray 300054-3PK) 83 
platform, while images were scanned using Agilent Microarray Scanner (G2565CA) controlled by Agilent Scan Control 7.0 84 
software. The total gene signals were extracted using the Imagene 6.0 software (Biodiscovery Inc., USA). MicroRNAs were 85 
considered significantly differentially expressed (DE) if they obtained a p-value<0.05 and an FDR≤0.05. 86 
 87 
MiRNA signature validation by quantitative Real-Time polymerase chain reaction (qRT-PCR)  88 
Expression measurements of selected miRNAs; hsa-miR-3138 and hsa-miR-1909* targets were studied in all samples 89 
screened (n=22) with miRNA microarrays using qRT-PCR, as described in Braoudaki et al. (2014). Briefly, qRT-PCR was 90 
performed using a standard Taqman PCR kit procedure on a LC480 LightCycler system (Roche GmbH, Switzerland). RNU44 91 
was used as a reference gene. Relative expression was calculated using the comparative ΔΔCt method [11]. 92 
 93 
Statistical Analysis 94 
The multiparameter analyses were performed with MATLAB® simulation environment (The Mathworks, Inc., Natick, MA). 95 
The two tailed student t-test was used to test the mean differences between two groups. Continuous variables are expressed as 96 
median±standard deviation unless indicated differently. Receiver Operating Characteristic (ROC) curves were established to 97 
evaluate the diagnostic value of deregulated miRNAs for differentiating between tumors (PAs and EPs) and controls. MiRNA 98 
expression analyses of association with clinical variables were conducted with the Kruskal Wallis test. Time to relapse and 99 
overall survival were also analyzed from different groups of clinical variables with the Kruskal Wallis test.   100 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
5 
 
RESULTS 101 
MicroRNA Expression and Patient Diagnosis 102 
In the current study, we identified a total of 120 DE miRNAs (p<0.05 and FDR<0.05) in the DNET tumor group when 103 
compared to the non-malignant group of patients. Overall, the majority of the DE miRNAs observed in DNETs were down-104 
regulated with a total of 70 miRNAs (58.3%) exhibiting decreased expression and 50 miRNAs (41.6%) showing increased 105 
expression (Figure 1).  106 
 107 
ROC Analysis 108 
ROC analysis of all miRNAs in each tumor type, using the microarray expression data, evaluated the extent to which they 109 
could separate the tumor entity from the control group.  MicroRNAs with a p<0.05 and an AUC>0.7 were selected as 110 
successful distinguishing markers between DNETs and the control group (Figure 2). More specifically, the ROC curves 111 
yielded the following AUCs: miR-101* (AUC=0.81, down-regulated), miR-186* (AUC=0.92, down-regulated), miR-1909* 112 
(AUC=0.99, up-regulated), miR-224* (AUC=0.86, down-regulated), miR-3138 (AUC=0.89, down-regulated), miR-363* 113 
(AUC=0.81, down-regulated), and miR-572 (AUC=0.94, down-regulated) were found to discriminate DNETs from controls. 114 
In particular, miR-1909* and miR-3138 once again appeared to discriminate DNETs from controls. 115 
 116 
MiRNA signature validation by qRT-PCR  117 
We examined by qRT-PCR the expression levels of miR-3138 and miR-1909* in a total of 22 samples including the patients 118 
and control cohorts (Figure 3). According to our results, miR-3138 was found down-regulated in all DNET samples screened, 119 
verifying the initial miRNA microarray findings. Regarding miR-1909*, qRT-PCR again verified the increased expression 120 
levels initially found in all DNET samples examined by miRNA microarrays.  121 
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DISCUSSION 123 
To date, a surge of interest is shown on the role of miRNAs in cancer, since several previous reports have suggested that the 124 
deregulation of miRNA molecules can have a dramatic biological and clinical impact. In addition, as has previously been 125 
reported, miRNA expression profiles can be used to distinguish between closely related tumor tissue subtypes and might 126 
provide a consistent diagnosis of the disease. In the current study, we examined miRNA signatures in pediatric patients with 127 
DNETs in an attempt to identify putative biomarkers predictive for the diagnosis of these infrequent epileptogenic tumors, 128 
which might inflict significant neurological and cognitive damage, despite the favorable survival rates.  129 
 130 
Specifically, herein, we compared the differential miRNA expression profiles between brain tissues resected from children 131 
diagnosed with DNETs and those collected during autopsy from diseased children that were not present with any brain 132 
distortion and were not diagnosed with any type of malignancy. Such comparisons are highly prominent, since the 133 
heterogeneity of the compared tissues might lead to the identification of putative reliable and robust miRNA biomarkers.   134 
 135 
By performing miRNA microarrays, overall 120 differentially expressed miRNAs between DNETs and the control cohort 136 
were identified. Quantitative RT-PCR measurement was used to validate the expression levels of two miRNAs; miR-3138 137 
and miR-1909*, whose differential expression was more pronounced. More specifically, miR-3138 was found down-regulated 138 
in the DNET cohort when compared to the control group. MiR-3138 was selected as a successful distinguishing marker 139 
between DNETs and the control cohort, according to ROC analyses findings (AUC=0.898). To our knowledge, limited reports 140 
have been found regarding the role of miR-3138 in cancer. Lone Zhang et al. [17], indicated that miR-3138 could enhance 141 
radioresistance in human cervical cancer cells.  142 
 143 
Regarding miR-1909*, markedly elevated levels of expression were detected in the DNET cohort, suggesting that it might 144 
possess oncogenic activities when overexpressed. It is also noteworthy, that mir-1909* was also detected following a fairly 145 
strict filtering approach in the ROC tests (AUC=0.998), verifying the possibility that it affords a distinguishing marker between 146 
the tumor types and the normal tissues. Yet again, to the best of our knowledge, thus far, no studies are available describing 147 
the value of miR-1909* in pediatric brain malignancies, whereas inadequate reports were found regarding their role in other 148 
types of cancer. In a similar context, Della Vittoria Scarpati et al. (2011) who studied miRNA signatures in locally advanced 149 
rectal cancer, found that miR-1909* was significantly upregulated in patients with less aggressive rectal cancer of tumor 150 
regression grade 1 [18].  151 
 152 
It is notable that by conducting ROC curves analyses, the diagnostic value of several additional miRNAs; miR-101*, miR-153 
186*, miR-363* miR-224*, and miR-572 was appraised with AUCs ranging from 0.807-0.941.  Of note, all aforementioned 154 
miRNAs were found to possess tumor suppressor properties in DNETs and for the majority of them, this is in line with other 155 
investigations which proposed similar properties in other types of cancers. For instance, previous reports have shown that mir-156 
101* participates in the carcinogenesis and tumor progression in various cancers. More specifically, decreased levels of 157 
expression of miR-101* have been reported in natural killer/T-cell lymphoma (NKTL) [19], in rhabdomyosarcoma [20] and 158 
in laryngeal squamous cell carcinoma [21].  Further on, the diminished expression of miR-186* has been detected in non-159 
small cell lung cancer [22, 23] and in bladder cancer [24]. The tumor suppressor properties of miR-363* has also been reported 160 
in hepatocellular carcinoma [25], in human head and neck squamous cell carcinoma [26], in NKTL [19] and in neuroblastoma 161 
tumorigenesis [27].  162 
 163 
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Our findings though are not in line with similar reports investigating the role of miR-224* and miR-572 in malignant diseases. 164 
According to selected studies, miR-574 possesses oncogenic properties in human ovarian cancer [28] and in early stage renal 165 
cell carcinoma [29]. As far as it concerns miR-224*, it is has been found overexpressed in diverse brain malignancies and 166 
notably in gliomas and medulloblastomas. More specifically, Lu et al. [30], suggested that miR-224* was associated with 167 
advanced pathological grade and was linked to inferior prognosis, whilst Kunder et al. (2013) reported that in 168 
medulloblastomas in the WNT subgroup, significant overexpression of miR-224* was noted [31]. 169 
 170 
Collectively, as previously reported by Braoudaki et al., (2014), it is probable if not assured that miRNAs play tissue specific 171 
roles and do not possess global tumour properties [11]. Therefore, it is essential to investigate their potential role in every 172 
tissue before entitling them either as oncogenes or tumour suppressor genes. Herein, our findings provided novel evidence 173 
regarding the potential role of several miRNAs and markedly for miR-3138 and miR-1909* in the pathogenesis of DNETs 174 
alone. Confirmation of larger scale prospective studies of children with DNETs and additional confirmatory experimentation 175 
are necessitated to unravel the described role of the aforementioned miRNAs. 176 
 177 
  178 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
8 
 
COMPETING INTERESTS 179 
The authors declare no competing financial or non-financial interests. 180 
Ethical approval: “All procedures performed in studies involving human participants were in accordance with the ethical 181 
standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later 182 
amendments or comparable ethical standards.” 183 
AUTHORS’ CONTRIBUTIONS: 184 
MB conceived and designed the study, performed all experiments, evaluated and interpreted data analyses, and drafted 185 
the manuscript. GIL performed all data analyses and participated in interpretation of data analyses SAP performed 186 
resections of the post-mortem specimens, KS performed tumor diagnosis, NP performed EK participated in the 187 
coordination and supervised the study. All authors approved the final manuscript. 188 
 189 
 190 
 191 
 192 
 193 
 194 
 195 
 196 
 197 
 198 
 199 
 200 
 201 
 202 
 203 
 204 
 205 
 206 
 207 
 208 
 209 
 210 
 211 
 212 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
9 
 
REFERENCES 213 
1. Chassoux F, Daumas-Duport C. Dysembryoplastic neuroepithelial tumors: where are we now? Epilepsia. 214 
2013;54 Suppl 9:129-34. doi:10.1111/epi.12457. 215 
2. Ranger A, Diosy D. Seizures in children with dysembryoplastic neuroepithelial tumors of the brain--A 216 
review of surgical outcomes across several studies. Childs Nerv Syst. 2015;31(6):847-55. doi:10.1007/s00381-217 
015-2675-9. 218 
3. Spalice A, Ruggieri M, Grosso S, Verrotti A, Polizzi A, Magro G et al. Dysembryoplastic neuroepithelial 219 
tumors: a prospective clinicopathologic and outcome study of 13 children. Pediatric neurology. 220 
2010;43(6):395-402. doi:10.1016/j.pediatrneurol.2010.06.017. 221 
4. Ozlen F, Gunduz A, Asan Z, Tanriverdi T, Ozkara C, Yeni N et al. Dysembryoplastic neuroepithelial tumors 222 
and gangliogliomas: clinical results of 52 patients. Acta neurochirurgica. 2010;152(10):1661-71. 223 
doi:10.1007/s00701-010-0696-4. 224 
5. Thom M, Toma A, An S, Martinian L, Hadjivassiliou G, Ratilal B et al. One hundred and one 225 
dysembryoplastic neuroepithelial tumors: an adult epilepsy series with immunohistochemical, molecular 226 
genetic, and clinical correlations and a review of the literature. Journal of neuropathology and experimental 227 
neurology. 2011;70(10):859-78. doi:10.1097/NEN.0b013e3182302475. 228 
6. Qaddoumi I, Ellison DW, Morris EB, Broniscer A, Boop F, Merchant T et al. Dysembryoplastic 229 
neuroepithelial tumors and cognitive outcome: cure at a price? Cancer. 2010;116(23):5461-9. 230 
doi:10.1002/cncr.25528. 231 
7. Maschio M, Sperati F, Dinapoli L, Vidiri A, Fabi A, Pace A et al. Weight of epilepsy in brain tumor patients. 232 
Journal of neuro-oncology. 2014;118(2):385-93. doi:10.1007/s11060-014-1449-7. 233 
8. Brinkman TM, Liptak CC, Delaney BL, Chordas CA, Muriel AC, Manley PE. Suicide ideation in pediatric 234 
and adult survivors of childhood brain tumors. Journal of neuro-oncology. 2013;113(3):425-32. 235 
doi:10.1007/s11060-013-1130-6. 236 
9. Tessitore A, Cicciarelli G, Mastroiaco V, Vecchio FD, Capece D, Verzella D et al. Therapeutic Use of 237 
MicroRNAs in Cancer. Anti-cancer agents in medicinal chemistry. 2015;16(1):7-19.  238 
10. Braoudaki M, Lambrou GI. MicroRNAs in pediatric central nervous system embryonal neoplasms: the 239 
known unknown. Journal of hematology & oncology. 2015;8(1):6. doi:10.1186/s13045-014-0101-5. 240 
11. Braoudaki M, Lambrou GI, Giannikou K, Milionis V, Stefanaki K, Birks DK et al. Microrna expression 241 
signatures predict patient progression and disease outcome in pediatric embryonal central nervous system 242 
neoplasms. Journal of hematology & oncology. 2014;7:96. doi:10.1186/s13045-014-0096-y. 243 
12. Ferretti E, De Smaele E, Miele E, Laneve P, Po A, Pelloni M et al. Concerted microRNA control of 244 
Hedgehog signalling in cerebellar neuronal progenitor and tumour cells. The EMBO journal. 245 
2008;27(19):2616-27. doi:10.1038/emboj.2008.172. 246 
13. Birks DK, Barton VN, Donson AM, Handler MH, Vibhakar R, Foreman NK. Survey of MicroRNA 247 
expression in pediatric brain tumors. Pediatric blood & cancer. 2011;56(2):211-6. doi:10.1002/pbc.22723. 248 
14. Wang F, Ren X, Zhang X. Role of microRNA-150 in solid tumors. Oncology letters. 2015;10(1):11-6. 249 
doi:10.3892/ol.2015.3170. 250 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
10 
 
15. Wang M, Deng X, Ying Q, Jin T, Li M, Liang C. MicroRNA-224 targets ERG2 and contributes to 251 
malignant progressions of meningioma. Biochemical and biophysical research communications. 252 
2015;460(2):354-61. doi:10.1016/j.bbrc.2015.03.038. 253 
16. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A et al. The 2007 WHO classification 254 
of tumours of the central nervous system. Acta neuropathologica. 2007;114(2):97-109. doi:10.1007/s00401-255 
007-0243-4. 256 
17. Zhang B, Chen J, Ren Z, Chen Y, Li J, Miao X et al. A specific miRNA signature promotes radioresistance 257 
of human cervical cancer cells. Cancer cell international. 2013;13(1):118. doi:10.1186/1475-2867-13-118. 258 
18. Della Vittoria Scarpati G, Falcetta F, Carlomagno C, Ubezio P, Marchini S, De Stefano A et al. A specific 259 
miRNA signature correlates with complete pathological response to neoadjuvant chemoradiotherapy in locally 260 
advanced rectal cancer. International journal of radiation oncology, biology, physics. 2012;83(4):1113-9. 261 
doi:10.1016/j.ijrobp.2011.09.030. 262 
19. Ng SB, Yan J, Huang G, Selvarajan V, Tay JL, Lin B et al. Dysregulated microRNAs affect pathways and 263 
targets of biologic relevance in nasal-type natural killer/T-cell lymphoma. Blood. 2011;118(18):4919-29. 264 
doi:10.1182/blood-2011-07-364224. 265 
20. Vella S, Pomella S, Leoncini PP, Colletti M, Conti B, Marquez VE et al. MicroRNA-101 is repressed by 266 
EZH2 and its restoration inhibits tumorigenic features in embryonal rhabdomyosarcoma. Clinical epigenetics. 267 
2015;7(1):82. doi:10.1186/s13148-015-0107-z. 268 
21. Li M, Tian L, Ren H, Chen X, Wang Y, Ge J et al. MicroRNA-101 is a potential prognostic indicator of 269 
laryngeal squamous cell carcinoma and modulates CDK8. Journal of translational medicine. 2015;13:271. 270 
doi:10.1186/s12967-015-0626-6. 271 
22. Cai J, Wu J, Zhang H, Fang L, Huang Y, Yang Y et al. miR-186 downregulation correlates with poor 272 
survival in lung adenocarcinoma, where it interferes with cell-cycle regulation. Cancer research. 273 
2013;73(2):756-66. doi:10.1158/0008-5472.can-12-2651. 274 
23. Cui G, Cui M, Li Y, Liang Y, Li W, Guo H et al. MiR-186 targets ROCK1 to suppress the growth and 275 
metastasis of NSCLC cells. Tumour biology : the journal of the International Society for Oncodevelopmental 276 
Biology and Medicine. 2014;35(9):8933-7. doi:10.1007/s13277-014-2168-6. 277 
24. Yao K, He L, Gan Y, Zeng Q, Dai Y, Tan J. MiR-186 suppresses the growth and metastasis of bladder 278 
cancer by targeting NSBP1. Diagnostic pathology. 2015;10:146. doi:10.1186/s13000-015-0372-3. 279 
25. Zhou P, Huang G, Zhao Y, Zhong D, Xu Z, Zeng Y et al. MicroRNA-363-mediated downregulation of 280 
S1PR1 suppresses the proliferation of hepatocellular carcinoma cells. Cellular signalling. 2014;26(6):1347-281 
54. doi:10.1016/j.cellsig.2014.02.020. 282 
26. Jamali Z, Asl Aminabadi N, Attaran R, Pournagiazar F, Ghertasi Oskouei S, Ahmadpour F. MicroRNAs 283 
as prognostic molecular signatures in human head and neck squamous cell carcinoma: a systematic review and 284 
meta-analysis. Oral oncology. 2015;51(4):321-31. doi:10.1016/j.oraloncology.2015.01.008. 285 
27. Qiao J, Lee S, Paul P, Theiss L, Tiao J, Qiao L et al. miR-335 and miR-363 regulation of neuroblastoma 286 
tumorigenesis and metastasis. Surgery. 2013;154(2):226-33. doi:10.1016/j.surg.2013.04.005. 287 
28. Zhang X, Liu J, Zang D, Wu S, Liu A, Zhu J et al. Upregulation of miR-572 transcriptionally suppresses 288 
SOCS1 and p21 and contributes to human ovarian cancer progression. Oncotarget. 2015;6(17):15180-93.  289 
29. Wang C, Hu J, Lu M, Gu H, Zhou X, Chen X et al. A panel of five serum miRNAs as a potential diagnostic 290 
tool for early-stage renal cell carcinoma. Scientific reports. 2015;5:7610. doi:10.1038/srep07610. 291 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
11 
 
30. Lu S, Wang S, Geng S, Ma S, Liang Z, Jiao B. Upregulation of microRNA-224 confers a poor prognosis 292 
in glioma patients. Clin Transl Oncol. 2013;15(7):569-74. doi:10.1007/s12094-012-0972-2. 293 
31. Kunder R, Jalali R, Sridhar E, Moiyadi A, Goel N, Goel A et al. Real-time PCR assay based on the 294 
differential expression of microRNAs and protein-coding genes for molecular classification of formalin-fixed 295 
paraffin embedded medulloblastomas. Neuro-oncology. 2013;15(12):1644-51. doi:10.1093/neuonc/not123. 296 
 297 
 298 
 299 
 300 
 301 
 302 
 303 
 304 
 305 
 306 
 307 
 308 
 309 
 310 
 311 
 312 
 313 
 314 
 315 
 316 
 317 
 318 
 319 
 320 
 321 
 322 
 323 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
12 
 
FIGURE LEGENDS 324 
Figure 1. Histogram graphical representations of the differentially expressed miRNAs between DNETs and the 325 
control group.  326 
 327 
Figure 2. Figure 2. ROC analysis using miRNA data. ROC curves of the most imperative DE miRNAs in DNETs 328 
identified in this study using the microarray expression data. Selected miRNAs could significantly separate control from 329 
DNET samples. In particular, miRNAs presented included miR-101* with AUC=0.81 (A), miR-186* with AUC=0.92 330 
(B), miR-1909* with AUC=0.99 (C), miR-224* with AUC=0.86 (D), mIR-3138 with AUC=0.89 (E), miR-363* with 331 
AUC=0.81 (F) and miR-572 with AUC=0.94 (G). 332 
 333 
Figure 3. Real-Time expression data of miR-3138 and miR-1909*. Comparative diagram of miRNA expression 334 
between microarray experimentation and qRT-PCR. Both methods validated the expression profiles of aforementioned 335 
miRNAs. 336 
 337 
 338 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
Figure 1 Click here to download Figure Figure 1_MO.tiff 
Figure 2 Click here to download Figure Figure 2_MO.tiff 
Figure 3 Click here to download Figure Figure 3_MO.tiff 
 Table 1: Patients’ clinicopathologic characterisitics 
 DNETs 
  
Median age (range in years) 7.07 
Gender (Male/Female)             2/3 
Tumor Anatomic Location  
Right Temporal Lobe 2 
Left Temporal Lobe 2 
Intraventicular Temporal Lobe 1 
Table 1 Click here to download Table Table 1.docx 
